Sirolimus to help prevent loss of daily function
Treatments studied
This Phase 2 trial studies whether sirolimus can slow or prevent functional decline (more difficulty with daily activities) in older adults. You may be considered if you’re in the right age range and have no major heart, lung, liver, kidney, or recent bleeding/clotting problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 65 to 80 (adult)
- Be postmenopausal, or have had surgical sterilization
- Have kidney function strong enough (creatinine clearance at least 30 mL/min)
- Do not have chronic liver disease
- Be free of certain recent problems (no major surgery/major injury, major bleeding/ulcers, or clot/stroke in the last 3–12 months)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called sirolimus to see if it can help older adults stay healthy and independent. The trial is looking for people aged 65 and older who live at home and do not have serious memory problems or major health conditions like kidney or liver disease.
This trial tests two FDA-approved drugs, rapamycin and everolimus, to see if they can improve immune function in healthy older adults. You may join if you are generally healthy, live independently, and are between 65 and 90 years old.
This early-phase study tests how a medicine called rapalog affects the body in generally healthy middle-aged adults. It may help researchers understand safety and dosing, but it’s not meant to treat an existing disease.
This Phase 2 trial tests sirolimus (a medicine that affects the immune system) to reduce symptoms and disease activity in adults with active systemic lupus erythematosus (SLE). You may be a good fit if your lupus is currently active despite stable standard treatments.
This Phase 2 study tests whether sirolimus, a medicine that changes immune and growth signals, can change what’s happening inside the tissue of unruptured brain aneurysms after a procedure. Researchers hope these molecular changes may help understand how to improve aneurysm outcomes.
This trial studies whether sirolimus can be used safely and works over time for LAM, a rare lung disease. You may be able to join if you already use (or cannot use) certain lung-targeting medicines called mTOR inhibitors, and if you can do regular clinic visits and breathing tests.
Hear when a new Aging trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.